


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app23.us.archive.org';v.server_ms=900;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712195229im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712195229im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712195229im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712195229im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712195229/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712195229im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712195229cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712195229js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712195229if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712195229/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712195229if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712195229/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712195229/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712195229/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712195229/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712195229/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712195229/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712195229/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712195229/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712195229/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712195229/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712195229/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712195229/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712195229/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712195229/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712195229/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712195229/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712195229/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712195229/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712195229/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712195229/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010824</li>
            <li>2015 Sep 15
            </li>            
                                </ul>
        <div>
                <h1>Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712195229/https://www.guideline.gov/search?f_Guideline_Developer_String=Program%20in%20Evidence-based%20Care&amp;fLockTerm=Program%2Bin%2BEvidence-based%2BCare">Program in Evidence-based Care</a></li>
                        <li>   
                                <a id="924" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A, Stem Cell Transplant Steering Committee. Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. Toronto (ON): Cancer Care Ontario (CCO); 2015 Sep 15. 45 p.&nbsp;(Evidence-based series; no. SCT-7).&nbsp; [33 references]</td></tr></table>                    <p><a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=fulltextlink&amp;redirect=https%253a%252f%252fwww.cancercare.on.ca%252fcommon%252fpages%252fUserFile.aspx%253ffileId%253d345925">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.</p>
<p>Please visit the <a href="https://web.archive.org/web/20180712195229/https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=345925" title="Cancer Care Ontario (CCO) Web site">Cancer Care Ontario (CCO) Web site</a> for details on any new evidence that has emerged and implications to the guidelines</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180712195229/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180712195229/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180712195229/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180712195229/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0376565&amp;fLockTerm=Anti-HIV+Agents">Anti-HIV Agents</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0079459&amp;fLockTerm=Granulocyte+Colony-Stimulating+Factor">Granulocyte Colony-Stimulating Factor</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0524864&amp;fLockTerm=Hematopoietic+Stem+Cell+Mobilization">Hematopoietic Stem Cell Mobilization</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0472699&amp;fLockTerm=Hematopoietic+Stem+Cell+Transplantation">Hematopoietic Stem Cell Transplantation</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0019398&amp;fLockTerm=Heterocyclic+Compounds">Heterocyclic Compounds</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0949573&amp;fLockTerm=HIV+Fusion+Inhibitors">HIV Fusion Inhibitors</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0019829&amp;fLockTerm=Hodgkin+Disease">Hodgkin Disease</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0024305&amp;fLockTerm=Lymphoma%2c+Non-Hodgkin">Lymphoma, Non-Hodgkin</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0026764&amp;fLockTerm=Multiple+Myeloma">Multiple Myeloma</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0027658&amp;fLockTerm=Neoplasms%2c+Germ+Cell+and+Embryonal">Neoplasms, Germ Cell and Embryonal</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MSH_CUI=C0040736&amp;fLockTerm=Transplantation%2c+Autologous">Transplantation, Autologous</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0205851&amp;fLockTerm=Germ+cell+tumor">Germ cell tumor</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0079459&amp;fLockTerm=Granulocyte+Colony-Stimulating+Factor">Granulocyte Colony-Stimulating Factor</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0949573&amp;fLockTerm=HIV+Fusion+Inhibitors">HIV Fusion Inhibitors</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0019829&amp;fLockTerm=Hodgkin%27s+Disease">Hodgkin&#39;s Disease</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0024305&amp;fLockTerm=Lymphoma%2c+Non-Hodgkin">Lymphoma, Non-Hodgkin</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0026764&amp;fLockTerm=Multiple+Myeloma">Multiple Myeloma</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_MTH_CUI=C0040736&amp;fLockTerm=Transplantation%2c+Autologous">Transplantation, Autologous</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712195229/https://www.guideline.gov/search?f_PDQ_CUI=C0019829&amp;fLockTerm=Hodgkin%27s+lymphoma">Hodgkin&#39;s lymphoma</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_PDQ_CUI=C0026764&amp;fLockTerm=multiple+myeloma">multiple myeloma</a>
, <a href="/web/20180712195229/https://www.guideline.gov/search?f_PDQ_CUI=C0024305&amp;fLockTerm=non-Hodgkin%27s+lymphoma">non-Hodgkin&#39;s lymphoma</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040736&amp;fLockTerm=Autogenous+transplantation">Autogenous transplantation</a>
 (53088000), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0079459&amp;fLockTerm=Colony-stimulating+factor%2c+granulocytic">Colony-stimulating factor, granulocytic</a>
 (80572003), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0205851&amp;fLockTerm=Germ+cell+tumor">Germ cell tumor</a>
 (115233005), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0205851&amp;fLockTerm=Germ+cell+tumor">Germ cell tumor</a>
 (402878003), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
 (234336002), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019398&amp;fLockTerm=Heterocyclic+compound">Heterocyclic compound</a>
 (116280007), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (118599009), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (118602004), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (118606001), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (14537002), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (46923007), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019829&amp;fLockTerm=Hodgkin+lymphoma">Hodgkin lymphoma</a>
 (74189002), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026764&amp;fLockTerm=Multiple+myeloma">Multiple myeloma</a>
 (109989006), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026764&amp;fLockTerm=Multiple+myeloma">Multiple myeloma</a>
 (55921005), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024305&amp;fLockTerm=Non-Hodgkin+lymphoma+(category)">Non-Hodgkin lymphoma (category)</a>
 (118601006), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024305&amp;fLockTerm=Non-Hodgkin+lymphoma+(category)">Non-Hodgkin lymphoma (category)</a>
 (128929007), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024305&amp;fLockTerm=Non-Hodgkin+lymphoma+(category)">Non-Hodgkin lymphoma (category)</a>
 (1929004), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1955474&amp;fLockTerm=Plerixafor">Plerixafor</a>
 (442206008), <a href="/web/20180712195229/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1955474&amp;fLockTerm=Plerixafor">Plerixafor</a>
 (442264009)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/downloadcontent/ngc-10824?contentType=pdf" class="pdf">.PDF 98.8 kb</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/downloadcontent/ngc-10824?contentType=word" class="word">Word Document 293.0 kb</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/downloadcontent/ngc-10824?contentType=xml" class="xml">.XML 39.9 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712195229/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712195229/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712195229/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712195229/mailto:/?Subject=AHRQ: Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario.&amp;body=https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2015 Sep 15. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879">RefWorks</a></li>
                            <li><a href="/web/20180712195229/https://www.guideline.gov/summaries/citedownload/49879?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="49879" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Recommendation 1</span></strong></p>
<p>Adding plerixafor to granulocyte colony-stimulating factor (G-CSF) is an option for initial mobilization for patients with non-Hodgkin lymphoma or multiple myeloma who are eligible for autologous stem cell transplantation (SCT) when chemotherapy cannot be used and only G-CSF mobilization is available.</p>
<p><strong><span style="text-decoration: underline;">Recommendation 2</span></strong></p>
<p>For patients with low peripheral blood CD34<sup>+</sup> cells counts (e.g., &lt;10/uL) at the time of anticipated stem cell harvesting, or with an inadequate first-day apheresis collection, it is recommended that plerixafor be added to the mobilization regimen to maximize stem cell collection and to prevent the need for remobilization.</p>
<p><strong><span style="text-decoration: underline;">Recommendation 3</span></strong></p>
<p>For patients who have failed a previous mobilization attempt, it is recommended that they undergo remobilization with G-CSF and plerixafor, with or without chemotherapy.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Any disease or condition requiring autologous hematopoietic stem cell transplantation (SCT), including non-Hodgkin and Hodgkin lymphoma, multiple myeloma, and germ cell tumours</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Hematology</p>
                    <p>Internal Medicine</p>
                    <p>Oncology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Health Care Providers</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To summarize the available data regarding the efficacy of plerixafor in enhancing hematopoietic stem cell mobilization and collection before autologous stem cell transplantation (SCT) and to provide recommendations on its use</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>All adult patients considered for autologous stem cell transplantation (SCT) and meeting one of the following criteria:</p>
<ul style="list-style-type: disc;">
    <li>Have not been mobilized before (i.e., the case of up front mobilization in na&iuml;ve patients who may or may not be at risk of being poor mobilizers) </li>
    <li>Are failing initial mobilization (based on peripheral blood CD34<sup>+</sup> cells count before first day of apheresis, or the total number of CD34<sup>+</sup> cells collected on the first day of apheresis) </li>
    <li>Have failed a prior mobilization attempt (i.e., are poor mobilizers) </li>
</ul></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p>Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization before autologous transplantation</p></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Total number of CD34<sup>+</sup> cells collected during apheresis </li>
    <li>Number of apheresis procedures </li>
    <li>Peripheral blood CD34<sup>+</sup> cells counts </li>
    <li>Proportion of patients who proceed to autologous stem cell transplantation (SCT) </li>
    <li>Survival rate (post-SCT and in untransplanted patients) </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Search for Existing Guidelines</span></strong></p>
<p>A search for existing guidelines is generally undertaken prior to searching for existing systematic reviews or primary literature. This is done with the goal of identifying existing guidelines for adaptation, using the ADAPTE framework, or endorsement in order to avoid the duplication of guideline development efforts across jurisdictions. For this document, the following sources were searched for existing guidelines that addressed the research questions:</p>
<ul style="list-style-type: disc;">
    <li>Practice Guideline Databases:
    <ul style="list-style-type: disc;">
        <li>the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.partnershipagainstcancer.ca%2fsage-standards-and-guidelines-evidence%2f" title="SAGE Web site">Standards and Guidelines Evidence Directory of Cancer Guidelines (SAGE)</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>, and </li>
        <li>the <a href="https://web.archive.org/web/20180712195229/http://www.guideline.gov/" target="_blank" title="NGC Web site">Agency for Healthcare Research and Quality (AHRQ) National Guideline Clearinghouse (NGC)</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> </li>
    </ul>
    </li>
    <li>Electronic Databases: MEDLINE and EMBASE </li>
</ul>
<p>Guidelines that were considered relevant to the objectives and the research questions were then evaluated for quality using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. Two guidelines were identified as potentially relevant and considered for full text review and quality assessment using the AGREE II instrument. However, the reporting quality was low, taking into consideration the methods used to search for the evidence, the methods used to formulate the recommendations, and the criteria for selecting the evidence. In addition stakeholder involvement, among other domains needed for undergoing quality assurance, was not reported. For these reasons, the recommendations made in these two guidelines were not considered for endorsement or adaptation and no quality assessment was conducted.</p>
<p>This evidence review was conducted in two planned stages, including a search for systematic reviews followed by a search for primary literature.</p>
<p><strong><span style="text-decoration: underline;">Search for Existing Systematic Reviews</span></strong></p>
<p>The Cochrane Database of Systematic Reviews was searched from January 2009 to April 2014 using the word "plerixafor". Systematic reviews older than six years were considered not relevant, because the main goal of a search for systematic reviews is to identify recent secondary sources covering the primary literature that may be helpful in the development of these recommendations.</p>
<p>Systematic reviews were included if:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>The existing systematic review searched for studies evaluating the efficacy of plerixafor in enhancing hematopoietic stem cell mobilization and collection in adult or pediatric patients considered for autologous stem cell transplantation (SCT) </li>
    <li>The literature search strategy for the existing review was reproducible and appropriate </li>
    <li>The existing systematic review reported the sources searched as well as the dates that were searched </li>
</ol>
<p>Identified systematic reviews that met the eligibility criteria would be assessed using the Assessing Methodological Quality of Systematic Reviews (AMSTAR) tool (a measurement tool to assess the methodological quality of systematic reviews) to determine whether or not an existing review could be incorporated as part of the evidentiary base. Any identified reviews that did not meet the criteria above, whose AMSTAR assessments indicated important deficiencies in quality, or that were otherwise not incorporated as part of the evidence base would be reported in the reference list, but not further described or discussed.</p>
<p><strong><span style="text-decoration: underline;">Search for Primary Literature</span></strong></p>
<p><strong>Literature Search Strategy</strong></p>
<p>The MEDLINE (Ovid) (1996 through April 18, 2014) and EMBASE (Ovid) (1996 through Week 16, 2014) databases were searched for evidence in April 2014 and updated in March 2015. The search strategy included a logical combination of terms for the condition (stem cell transplantation), the intervention (plerixafor), and studies of interest (systematic reviews, clinical trials, nonrandomized studies with an appropriate control group). The full literature strategy used to retrieve potential relevant studies is presented in Appendix 1 of the original guideline document.</p>
<p><strong>Study Selection Criteria and Protocol</strong></p>
<p><em>Inclusion Criteria</em></p>
<p>Articles identified in this literature search were eligible for inclusion if they met the following criteria:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>Primary studies evaluating the efficacy of plerixafor in enhancing hematopoietic stem cell mobilization and collection before autologous SCT </li>
    <li>Published full-report articles of randomized control trials and nonrandomized studies with an appropriate contemporaneous control group </li>
    <li>Studies reporting the outcomes of interest such as number of CD34<sup>+</sup> cells collected, number of apheresis procedures, proportion of patients who proceed to autologous SCT, and survival rate post-SCT </li>
</ol>
<p><em>Exclusion Criteria</em></p>
<p>Studies were excluded if they were:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>Abstracts, letters, case reports, comments, books, notes, or editorial-type publications </li>
    <li>Because resources were not available for translation services, articles published in a language other than English </li>
</ol>
<p>A review of the titles and abstracts that resulted from the search was conducted by one reviewer, and the reference list from these sources was searched for additional trials. For those items that warranted full text review, the same reviewer assessed each item independently.</p>
<p><strong><span style="text-decoration: underline;">Results</span></strong></p>
<p><strong>Search for Existing Systematic Reviews</strong></p>
<p>The Cochrane Collaboration released a systematic review protocol in 2013 to evaluate the efficacy and safety of plerixafor for the mobilization of hematopoietic stem cells in people with non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma and with the indication for autologous transplantation, but a full report has not been published yet. No other relevant systematic reviews were identified.</p>
<p><strong>Systematic Review of the Primary Literature</strong></p>
<p><em>Literature Search Results</em></p>
<p>While reviewing the primary literature few studies were identified that met the initial inclusion criteria, and therefore a post hoc subset of nonrandomized studies with historical groups was included, because these types of studies would help to inform the recommendations. Similarly, due to the shortage of comparative studies assessing the efficacy of plerixafor in both patients failing mobilization prior to autologous SCT, and patients who have failed a prior mobilization regimen, the inclusion criteria for this population was expanded to include single-arm studies with a sample size of at least 30 participants.</p>
<p>As presented in Figure 1 of the original guideline document, out of 2576 titles and abstracts identified in the search of the MEDLINE and EMBASE databases, 2302 appeared potentially eligible on initial review, and 160 of these were verified to be eligible for full text review. Eight additional studies were included for full text review based on the updated search in 2015. From these, 22 full-report studies were identified that evaluated the efficacy of plerixafor in enhancing hematopoietic stem cell mobilization and collection before autologous SCT, and reported the outcome of interest. The remaining 146 studies were excluded because they failed to pass the inclusion criteria.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Search for Existing Systematic Reviews</span></strong> </p>
<p>No relevant systematic reviews were identified.</p>
<p><strong><span style="text-decoration: underline;">Search for Primary Literature</span></strong></p>
<p>Twenty-two full-report studies met the inclusion criteria.</p>
<p>See Figure 1 in the original guideline document for a flow diagram depicting the study selection process.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Data Extraction</span></strong></p>
<p>Data extraction was conducted by one reviewer. All extracted data and information was assessed by a second reviewer, and audited by an independent auditor to verify the accuracy of the information obtained from the studies included in this report. For primary studies, key characteristics, including author, year of publication, study design, sample size, treatment arms, plerixafor indication/diagnosis, intervention and mobilization regimen, and years of data collection were extracted. Outcomes of interest including number of CD34<sup>+</sup> cells collected, number of apheresis procedures, proportion of patients who proceed to autologous stem cell transplantation (SCT), survival rate post SCT, and survival rate in untransplanted patients were extracted when available.</p>
<p><strong><span style="text-decoration: underline;">Assessment of Study Quality</span></strong></p>
<p>For systematic reviews that would be used as the sole evidence base for the recommendations, the Assessing Methodological Quality of Systematic Reviews (AMSTAR) tool (a measurement tool to assess the methodological quality of systematic reviews) would be used to assess quality. For clinical practice guidelines (CPGs), the Appraisal of Guidelines Research &amp; Evaluation (AGREE) II instrument would be used to assess quality. However, because of the time and effort necessary to properly implement the AGREE II instrument, it would be used only if adaptation of the recommendations was considered feasible by the members of the Working Group given the nature and coverage of the guideline and an informal assessment of the guideline's methods. Where recommendations from CPGs were not adapted, the evidence base in those CPGs would be informally assessed for completeness, and any relevant evidence within would be considered as a basis for recommendations in this report. Any meta-analysis would be assessed for quality using similar criteria as used for randomized controlled trials (RCTs), where appropriate. RCTs would be assessed for quality by examining the following seven criteria: method of randomization, reporting of blinding, power and sample size calculation, length of follow-up, reporting details of the statistical analysis, reporting on withdrawals to treatment and other losses to follow-up, and reporting on the sources of funding for the research. Comparative, nonrandomized, and single-arm evidence would be assessed according to full reporting of the patient selection criteria, the interventions each patient received, all relevant outcomes, and the source of funding. All authors reviewed and discussed a draft of this report with the aim of assessing the quality of the evidence as a whole, without the use of a scoring system or cut-offs, according to the policy of the Program in Evidence-Based Care (PEBC).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Recommendation Report Developers</span></strong></p>
<p>This recommendation report was developed by a Working Group consisting of four haematologists/oncologists and a health research methodologist at the request of the Stem Cell Transplant Committee.</p>
<p>The Working Group was responsible for reviewing the evidence base, drafting the recommendations and responding to comments received during the document review process.</p>
<p><strong><span style="text-decoration: underline;">Recommendation Report Development Methods</span></strong></p>
<p>The Program in Evidence-Based Care (PEBC) produces evidence-based and evidence-informed guidance documents using the methods of the Practice Guidelines Development Cycle. For Recommendation Reports this process includes a systematic review, interpretation of the evidence by the Working Group and draft recommendations, internal review by a methodology experts and final approval by the Sponsoring Committee.</p>
<p>The PEBC uses the Appraisal of Guidelines Research &amp; Evaluation (AGREE) II framework as a methodological strategy for guideline development. AGREE II is a 23-item validated tool that is designed to assess the methodological rigour and transparency of guideline development.</p>
<p><strong>Research Questions</strong></p>
<p>The following research questions were developed to direct the search for available evidence to inform recommendations:</p>
<ul style="list-style-type: disc;">
    <li>Does the administration of plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization before autologous transplantation improve the outcome of patients who have not been mobilized before, when compared with G-CSF for stem cell mobilization alone or in combination with chemotherapy? </li>
    <li>Does the administration of plerixafor in combination with G-CSF for stem cell mobilization before autologous transplantation improve the outcome of patients failing mobilization when compared with G-CSF for stem cell mobilization alone or in combination with chemotherapy? </li>
    <li>Does the administration of plerixafor in combination with G-CSF for stem cell mobilization before autologous transplantation improve the outcome of patients who have failed a prior mobilization regimen when compared with G-CSF for stem cell mobilization alone or in combination with chemotherapy? </li>
</ul></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>Evidence on the cost-effectiveness of plerixafor was not considered in this report.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Recommendation Report Review and Approval</span></strong></p>
<p><strong>Internal Review</strong></p>
<p>The recommendation report was reviewed by the Director of the Program in Evidence-Based Care (PEBC). The Working Group is responsible for ensuring the necessary changes are made. If those changes could be made without substantially altering the recommendations, the altered draft would not need to be resubmitted for approval again.</p>
<p><strong>Report Approval by the Stem Cell Transplant Steering Committee</strong></p>
<p>After internal review, the report was presented to the Cancer Care Ontario-Stem Cell Transplant Steering Committee (CCO-SCT). Members of the CCO-SCT reviewed the report, and formally approved the document during a meeting held on Thursday, September 10th, 2015.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The recommendations are supported by randomized controlled trials (RCTs), non-randomized controlled trials, retrospective cohorts, and single arm trials.</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>The use of plerixafor plus granulocyte colony-stimulating factor (G-CSF) "on demand" for those patients who appear to be mobilizing poorly was felt to be a useful strategy to maximize the benefits of plerixafor, minimize the risk of requiring remobilization, and therefore allow patients to proceed to transplant in a timely fashion. With many health-care centres opting to use plerixafor plus G-CSF "on demand" in poor mobilizers, the number of patients requiring remobilization is expected to decrease over time.</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario (CCO) makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. </li>
    <li>See the original guideline document for qualifying statements related to each specific recommendation. </li>
</ul></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Quick Reference Guides/Physician Guides</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A, Stem Cell Transplant Steering Committee. Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. Toronto (ON): Cancer Care Ontario (CCO); 2015 Sep 15. 45 p.&nbsp;(Evidence-based series; no. SCT-7).&nbsp; [33 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2015 Sep 15</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]</p>
                        <h3><a href="#">Guideline Developer Comment</a></h3>
                    <p><div class="content_para"><p>The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care.</p></div></p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario (CCO) supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ontario Ministry of Health and Long-Term Care.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Plerixafor Working Group</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Working Group Members</em>: C.T. Kouroukis, N.P. Varela, C. Bredeson, J. Kuruvilla, A. Xenocostas, Stem Cell Transplant Steering Committee</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Members of the Plerixafor Working Group and Their Conflict of Interest Declaration</span></strong></p>
<p>In accordance with the Program in Evidence-based Care (PEBC) Conflict of Interest (COI) Policy, the authors of this recommendation report and internal reviewers were asked to disclose potential conflicts of interest. One author declared no conflicts of interest, and four (TK, CB, JK, AX) declared conflicts. TK reported receiving honoraria for work regarding plerixafor as a clinical reviewer for the Canadian Agency for Drugs and Technologies in Health. CB reported being the president-elect of the Canadian Blood and Marrow Transplant Group, which had received $5000 or more in a single year from Sanofi, the clinical developer of plerixafor. CB, JK, and AX declared that they had received research grant support from Sanofi. JK also declared that he had been a principal investigator for a clinical trial involving plerixafor.</p>
<p>The COIs declared above did not disqualify any individuals from performing their designated role in the development of this guideline, in accordance with the PEBC COI Policy. To obtain a copy of the policy, please contact the PEBC office by e-mail at <a href="https://web.archive.org/web/20180712195229/mailto:ccopgi@mcmaster.ca">ccopgi@mcmaster.ca</a>.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.</p>
<p>Please visit the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.cancercare.on.ca%2fcommon%2fpages%2fUserFile.aspx%3ffileId%3d345925" title="Cancer Care Ontario (CCO) Web site">Cancer Care Ontario (CCO) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> for details on any new evidence that has emerged and implications to the guidelines</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.cancercare.on.ca%2fcommon%2fpages%2fUserFile.aspx%3ffileId%3d345925" title="Cancer Care Ontario (CCO) Web site">Cancer Care Ontario (CCO) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Plerixafor for autologous hematopoietic stem cell mobilization and transplantation for patients in Ontario. Summary. Toronto (ON): Cancer Care Ontario (CCO); 2015 Sep 15. 6 p. Available from the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.cancercare.on.ca%2fcommon%2fpages%2fUserFile.aspx%3ffileId%3d345927" title="Cancer Care Ontario (CCO) Web site">Cancer Care Ontario (CCO) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Program in Evidence-based Care handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Available from the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.cancercare.on.ca%2fcommon%2fpages%2fUserFile.aspx%3ffileId%3d50876" title="Cancer Care Ontario (CCO) Web site">CCO Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Program in Evidence-based Care methods handbook. Toronto (ON): Cancer Care Ontario (CCO); 2014 Sep 23. Available from the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=http%3a%2f%2fpebctoolkit.mcmaster.ca%2fdoku.php%3fid%3dprojectdev%3apebc_methods_handbook%26" title="PEBC Toolkit Web site">Program in Evidence-based Care (PEBC) Toolkit Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Program in Evidence-based Care document assessment and review protocol. Toronto (ON): Cancer Care Ontario (CCO); 2015 Apr 16. 15 p. Available from the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.cancercare.on.ca%2fcommon%2fpages%2fUserFile.aspx%3ffileId%3d285439" title="Cancer Care Ontario (CCO) Web site">CCO Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on January 4, 2016.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the <a href="/web/20180712195229/https://www.guideline.gov/Home/Disclaimer?id=49879&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.cancercare.on.ca%2fontariocancernews%2fcopyright.html" title="Cancer Care Ontario (CCO) Web site">Copyright and Disclaimer Statements</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712195229im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> posted at the Program in Evidence-based Care section of the Cancer Care Ontario (CCO) Web site.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712195229/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712195229/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712195229/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712195229/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712195229/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712195229/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712195229/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712195229/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712195229/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712195229/https://www.guideline.gov/disclaimer?id=49879&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712195229/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712195229/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712195229/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712195229/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712195229/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712195229/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712195229/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712195229/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712195229/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712195229/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712195229/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712195229/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712195229/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712195229im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712195229/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712195229/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712195229js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712195229js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 19:52:29 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:23:50 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 384.646 (3)
  esindex: 0.011
  captures_list: 402.163
  CDXLines.iter: 13.264 (3)
  PetaboxLoader3.datanode: 41.616 (4)
  exclusion.robots: 0.267
  exclusion.robots.policy: 0.248
  RedisCDXSource: 0.648
  PetaboxLoader3.resolve: 430.726
  load_resource: 458.15
-->